糖尿病性神経障害治療薬の世界市場（～2026年）

• 英文タイトル：Global Diabetic Neurological Disorder Therapeutic Drug Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11634 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は糖尿病性神経障害治療薬のグローバル市場について調査・分析したレポートです。種類別（カプセル、丸薬、その他）市場規模、用途別（対称性ニューロパシー、焦点・多巣性ニューロパシー）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別糖尿病性神経障害治療薬の競争状況、市場シェア ・世界の糖尿病性神経障害治療薬市場：種類別市場規模 2015年-2020年（カプセル、丸薬、その他） ・世界の糖尿病性神経障害治療薬市場：種類別市場規模予測 2021年-2026年（カプセル、丸薬、その他） ・世界の糖尿病性神経障害治療薬市場：用途別市場規模 2015年-2020年（対称性ニューロパシー、焦点・多巣性ニューロパシー） ・世界の糖尿病性神経障害治療薬市場：用途別市場規模予測 2021年-2026年（対称性ニューロパシー、焦点・多巣性ニューロパシー） ・北米の糖尿病性神経障害治療薬市場分析：米国、カナダ ・ヨーロッパの糖尿病性神経障害治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの糖尿病性神経障害治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の糖尿病性神経障害治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの糖尿病性神経障害治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Johnson & Johnson、Takeda、Mitsubishi Chemical、Avanir Pharmaceuticals、Dong-A Pharmaceutical Co., Ltd.、Immune Pharmaceuticals、MediciNova、Sangamo BioSciences ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

A drug used to treat mental illness caused by diabetes

Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market
The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Neurological Disorder Therapeutic Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Neurological Disorder Therapeutic Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Neurological Disorder Therapeutic Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Neurological Disorder Therapeutic Drug market.

Global Diabetic Neurological Disorder Therapeutic Drug Scope and Market Size
Diabetic Neurological Disorder Therapeutic Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Neurological Disorder Therapeutic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Capsule
Pills
Other

Market segment by Application, split into
Symmetrical Neuropathy
Focal and Multifocal Neuropathy

Based on regional and country-level analysis, the Diabetic Neurological Disorder Therapeutic Drug market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Diabetic Neurological Disorder Therapeutic Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
AstraZeneca
Johnson & Johnson
Takeda
Mitsubishi Chemical
Avanir Pharmaceuticals
Dong-A Pharmaceutical Co., Ltd.
Immune Pharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Capsule
1.2.3 Pills
1.2.4 Other
1.3 Market by Application
1.3.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Application: 2020 VS 2026
1.3.2 Symmetrical Neuropathy
1.3.3 Focal and Multifocal Neuropathy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Perspective (2015-2026)
2.2 Global Diabetic Neurological Disorder Therapeutic Drug Growth Trends by Regions
2.2.1 Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Neurological Disorder Therapeutic Drug Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Neurological Disorder Therapeutic Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Neurological Disorder Therapeutic Drug Players by Market Size
3.1.1 Global Top Diabetic Neurological Disorder Therapeutic Drug Players by Revenue (2015-2020)
3.1.2 Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Players (2015-2020)
3.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Neurological Disorder Therapeutic Drug Revenue
3.4 Global Diabetic Neurological Disorder Therapeutic Drug Market Concentration Ratio
3.4.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Neurological Disorder Therapeutic Drug Revenue in 2019
3.5 Key Players Diabetic Neurological Disorder Therapeutic Drug Area Served
3.6 Key Players Diabetic Neurological Disorder Therapeutic Drug Product Solution and Service
3.7 Date of Enter into Diabetic Neurological Disorder Therapeutic Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Diabetic Neurological Disorder Therapeutic Drug Breakdown Data by Type (2015-2026)
4.1 Global Diabetic Neurological Disorder Therapeutic Drug Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Neurological Disorder Therapeutic Drug Forecasted Market Size by Type (2021-2026)

5 Diabetic Neurological Disorder Therapeutic Drug Breakdown Data by Application (2015-2026)
5.1 Global Diabetic Neurological Disorder Therapeutic Drug Historic Market Size by Application (2015-2020)
5.2 Global Diabetic Neurological Disorder Therapeutic Drug Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Diabetic Neurological Disorder Therapeutic Drug Market Size (2015-2026)
6.2 North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020)
6.3 North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020)
6.4 North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size (2015-2026)
7.2 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020)
7.3 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020)
7.4 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Diabetic Neurological Disorder Therapeutic Drug Market Size (2015-2026)
8.2 China Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020)
8.3 China Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020)
8.4 China Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Diabetic Neurological Disorder Therapeutic Drug Market Size (2015-2026)
9.2 Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020)
9.3 Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020)
9.4 Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size (2015-2026)
10.2 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020)
10.3 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020)
10.4 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Introduction
11.1.4 AstraZeneca Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020))
11.1.5 AstraZeneca Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Introduction
11.2.4 Johnson & Johnson Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.2.5 Johnson & Johnson Recent Development
11.3 Takeda
11.3.1 Takeda Company Details
11.3.2 Takeda Business Overview
11.3.3 Takeda Diabetic Neurological Disorder Therapeutic Drug Introduction
11.3.4 Takeda Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.3.5 Takeda Recent Development
11.4 Mitsubishi Chemical
11.4.1 Mitsubishi Chemical Company Details
11.4.2 Mitsubishi Chemical Business Overview
11.4.3 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Introduction
11.4.4 Mitsubishi Chemical Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.4.5 Mitsubishi Chemical Recent Development
11.5 Avanir Pharmaceuticals
11.5.1 Avanir Pharmaceuticals Company Details
11.5.2 Avanir Pharmaceuticals Business Overview
11.5.3 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Introduction
11.5.4 Avanir Pharmaceuticals Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.5.5 Avanir Pharmaceuticals Recent Development
11.6 Dong-A Pharmaceutical Co., Ltd.
11.6.1 Dong-A Pharmaceutical Co., Ltd. Company Details
11.6.2 Dong-A Pharmaceutical Co., Ltd. Business Overview
11.6.3 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Introduction
11.6.4 Dong-A Pharmaceutical Co., Ltd. Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.6.5 Dong-A Pharmaceutical Co., Ltd. Recent Development
11.7 Immune Pharmaceuticals
11.7.1 Immune Pharmaceuticals Company Details
11.7.2 Immune Pharmaceuticals Business Overview
11.7.3 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Introduction
11.7.4 Immune Pharmaceuticals Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.7.5 Immune Pharmaceuticals Recent Development
11.8 MediciNova
11.8.1 MediciNova Company Details
11.8.2 MediciNova Business Overview
11.8.3 MediciNova Diabetic Neurological Disorder Therapeutic Drug Introduction
11.8.4 MediciNova Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.8.5 MediciNova Recent Development
11.9 Sangamo BioSciences
11.9.1 Sangamo BioSciences Company Details
11.9.2 Sangamo BioSciences Business Overview
11.9.3 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Introduction
11.9.4 Sangamo BioSciences Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
11.9.5 Sangamo BioSciences Recent Development

12Analyst’s Viewpoints/Conclusions

13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Capsule
Table 4. Key Players of Pills
Table 5. Key Players of Other
Table 6. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 7. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 8. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions (2015-2020) (US$ Million)
Table 9. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Regions (2015-2020)
Table 10. Global Diabetic Neurological Disorder Therapeutic Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 11. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Regions (2021-2026)
Table 12. Diabetic Neurological Disorder Therapeutic Drug Market Market Trends
Table 13. Diabetic Neurological Disorder Therapeutic Drug Market Drivers
Table 14. Diabetic Neurological Disorder Therapeutic Drug Market Challenges
Table 15. Diabetic Neurological Disorder Therapeutic Drug Market Restraints
Table 16. Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Players (2015-2020) (US$ Million)
Table 17. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Players (2015-2020)
Table 18. Global Top Diabetic Neurological Disorder Therapeutic Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neurological Disorder Therapeutic Drug as of 2019)
Table 19. Global Diabetic Neurological Disorder Therapeutic Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Diabetic Neurological Disorder Therapeutic Drug Product Solution and Service
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 24. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Share by Type (2015-2020)
Table 25. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Type (2021-2026)
Table 26. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Share by Application (2015-2020)
Table 27. Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 28. Global Diabetic Neurological Disorder Therapeutic Drug Market Size Share by Application (2021-2026)
Table 29. North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 30. North America Diabetic Neurological Disorder Therapeutic Drug Market Share by Type (2015-2020)
Table 31. North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 32. North America Diabetic Neurological Disorder Therapeutic Drug Market Share by Application (2015-2020)
Table 33. North America Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (US$ Million) (2015-2020)
Table 34. North America Diabetic Neurological Disorder Therapeutic Drug Market Share by Country (2015-2020)
Table 35. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 36. Europe Diabetic Neurological Disorder Therapeutic Drug Market Share by Type (2015-2020)
Table 37. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 38. Europe Diabetic Neurological Disorder Therapeutic Drug Market Share by Application (2015-2020)
Table 39. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (US$ Million) (2015-2020)
Table 40. Europe Diabetic Neurological Disorder Therapeutic Drug Market Share by Country (2015-2020)
Table 41. China Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 42. China Diabetic Neurological Disorder Therapeutic Drug Market Share by Type (2015-2020)
Table 43. China Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 44. China Diabetic Neurological Disorder Therapeutic Drug Market Share by Application (2015-2020)
Table 45. China Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (US$ Million) (2015-2020)
Table 46. China Diabetic Neurological Disorder Therapeutic Drug Market Share by Region (2015-2020)
Table 47. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 48. Japan Diabetic Neurological Disorder Therapeutic Drug Market Share by Type (2015-2020)
Table 49. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 50. Japan Diabetic Neurological Disorder Therapeutic Drug Market Share by Application (2015-2020)
Table 51. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (US$ Million) (2015-2020)
Table 52. Japan Diabetic Neurological Disorder Therapeutic Drug Market Share by Country (2015-2020)
Table 53. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2015-2020) (US$ Million)
Table 54. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Share by Type (2015-2020)
Table 55. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2015-2020) (US$ Million)
Table 56. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Share by Application (2015-2020)
Table 57. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (US$ Million) (2015-2020)
Table 58. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Share by Country (2015-2020)
Table 59. AstraZeneca Company Details
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Product
Table 62. AstraZeneca Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 63. AstraZeneca Recent Development
Table 64. Johnson & Johnson Company Details
Table 65. Johnson & Johnson Business Overview
Table 66. Johnson & Johnson Product
Table 67. Johnson & Johnson Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 68. Johnson & Johnson Recent Development
Table 69. Takeda Company Details
Table 70. Takeda Business Overview
Table 71. Takeda Product
Table 72. Takeda Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 73. Takeda Recent Development
Table 74. Mitsubishi Chemical Company Details
Table 75. Mitsubishi Chemical Business Overview
Table 76. Mitsubishi Chemical Product
Table 77. Mitsubishi Chemical Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 78. Mitsubishi Chemical Recent Development
Table 79. Avanir Pharmaceuticals Company Details
Table 80. Avanir Pharmaceuticals Business Overview
Table 81. Avanir Pharmaceuticals Product
Table 82. Avanir Pharmaceuticals Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 83. Avanir Pharmaceuticals Recent Development
Table 84. Dong-A Pharmaceutical Co., Ltd. Company Details
Table 85. Dong-A Pharmaceutical Co., Ltd. Business Overview
Table 86. Dong-A Pharmaceutical Co., Ltd. Product
Table 87. Dong-A Pharmaceutical Co., Ltd. Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 88. Dong-A Pharmaceutical Co., Ltd. Recent Development
Table 89. Immune Pharmaceuticals Company Details
Table 90. Immune Pharmaceuticals Business Overview
Table 91. Immune Pharmaceuticals Product
Table 92. Immune Pharmaceuticals Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 93. Immune Pharmaceuticals Recent Development
Table 94. MediciNova Business Overview
Table 95. MediciNova Product
Table 96. MediciNova Company Details
Table 97. MediciNova Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 98. MediciNova Recent Development
Table 99. Sangamo BioSciences Company Details
Table 100. Sangamo BioSciences Business Overview
Table 101. Sangamo BioSciences Product
Table 102. Sangamo BioSciences Revenue in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020) (US$ Million)
Table 103. Sangamo BioSciences Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Type: 2020 VS 2026
Figure 2. Capsule Features
Figure 3. Pills Features
Figure 4. Other Features
Figure 5. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Application: 2020 VS 2026
Figure 6. Symmetrical Neuropathy Case Studies
Figure 7. Focal and Multifocal Neuropathy Case Studies
Figure 8. Diabetic Neurological Disorder Therapeutic Drug Report Years Considered
Figure 9. Global Diabetic Neurological Disorder Therapeutic Drug Market Size (US$ Million), YoY Growth 2015-2026
Figure 10. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Regions: 2020 VS 2026
Figure 11. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Regions (2021-2026)
Figure 12. Global Diabetic Neurological Disorder Therapeutic Drug Market Share by Players in 2019
Figure 13. Global Top Diabetic Neurological Disorder Therapeutic Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neurological Disorder Therapeutic Drug as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Diabetic Neurological Disorder Therapeutic Drug Revenue in 2019
Figure 15. North America Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 16. United States Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 17. Canada Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. Europe Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Germany Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. France Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. U.K. Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Italy Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Russia Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Nordic Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Rest of Europe Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. China Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Japan Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. South Korea Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. India Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Australia Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Rest of Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Latin America Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Mexico Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Brazil Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Turkey Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Saudi Arabia Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. UAE Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Rest of Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. AstraZeneca Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 43. Johnson & Johnson Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 44. Takeda Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 45. Mitsubishi Chemical Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 46. Avanir Pharmaceuticals Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 47. Dong-A Pharmaceutical Co., Ltd. Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 48. Immune Pharmaceuticals Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 49. MediciNova Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 50. Sangamo BioSciences Revenue Growth Rate in Diabetic Neurological Disorder Therapeutic Drug Business (2015-2020)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

---